Nurix Therapeutics (NRIX) Current Deferred Revenue (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Current Deferred Revenue for 8 consecutive years, with $13.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Current Deferred Revenue fell 51.41% year-over-year to $13.3 million; the TTM figure through May 2026 stood at $13.3 million (down 51.41% YoY), while the FY2025 annual figure was $17.6 million, down 54.18% from the prior year.
• Current Deferred Revenue slipped to $13.3 million in Q2 2026 per NRIX's latest filing, from $18.8 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $48.1 million in Q4 2023 and bottomed at $13.3 million in Q2 2026.
• Historically, Current Deferred Revenue has averaged $35.2 million across 5 years, with a median of $38.0 million in 2022.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue surged 49.82% — and 2025, when it plunged 54.18%.
• Nurix Therapeutics' Current Deferred Revenue stood at $37.6 million in 2022, then climbed by 27.81% to $48.1 million in 2023, then fell by 20.24% to $38.4 million in 2024, then slumped by 54.18% to $17.6 million in 2025, then declined by 24.21% to $13.3 million in 2026.
• Business Quant data shows NRIX's Current Deferred Revenue at $13.3 million in Q2 2026, $18.8 million in Q1 2026, and $17.6 million in Q4 2025.